

**REMARKS**

This Application has been carefully reviewed in light of the Office Action mailed May 1, 2008. Claims 1-27 are in this Application. Claims 1-11, 13 and 16 were withdrawn previously. Claims 12 and 14 are amended. Claims 28-35 have been added. No claim has been canceled. Claims 12, 14-15, and 17-34 are pending for examination.

In the Office Action, Claims 12, 14-15, and 17-27 were rejected under 35 U.S.C. § 112, first paragraph for lacking enablement on the basis that the specification does not reasonably provide enablement for preventing or inhibiting neuronal cell death in a mammal comprising administration of GW5074 (GW) and XM336372 (ZM) when the claims are broadly interpreted to mean *complete* prevention or inhibition. (pages 2 and 4 of the Office Action). Independent Claims 12 and 14 have been amended to recite that the inhibition is at least partial and is supported by the specification and drawings as noted at page 4 of the Office Action. However, one of ordinary or even minor skill would easily observe complete inhibition, for example, by increasing dosage, with some routine experimentation based on the working examples provided in the specification. Routine experimentation does not rise to the level of being undue. MPEP 2164.06. In general the Examiner has not provided any evidence or reasoning to support the assertion that complete inhibition is unlikely with reasonable experimentation and it respectfully submitted that a prima facie case of nonenablement has not been established. MPEP 2164.04.

New Claims 28 to 34 are presented for examination. Claim 28 recites a method of reducing neuronal cell death in a mammal comprising administering an effective amount of a C-Raf inhibitor or a pharmaceutically acceptable salt, complex or prodrug thereof. Dependent Claim 29 recites that the C-Raf inhibitor comprises an oxindole derivative and Claim 30 recites

that the C-Raf inhibitor comprises a benzamide derivative. Claims 31 and 32 recite that the C-Raf inhibitor of Claim 28 reduces neuronal cell death via B-Raf regulation and B-Raf activation, respectively. Claims 33 and 34 recite that the C-Raf inhibitor recited in Claims 29 or 31 or 32 comprises {5- iodo-3-[(3,5-dibromo-4-hydroxyphenyl) methylene]-2-indolinone} and N-[5-(3-dimethylaminobenzamide)-2-methylphenyl]-4-hydroxybenzamide, respectively.

Applicant has made a diligent effort to amend claims and to point out with particularity the patentability of the claims. Accordingly, Applicant earnestly solicits reconsideration for allowance of Claims 12, 14-15, and consideration for allowance of new Claims 17-34.

If the Examiner believes that an interview may advance prosecution of this Application, Applicant invites the Examiner to call the Applicant's representative below at 214.999.4712. In the event that any additional time is needed for this filing, or any additional time in excess of that requested in a petition for an extension of time, please consider this a petition for an extension of time for any needed extension pursuant to 37 C.F.R. § 1.136 or any other section or provision of Title 37. To the extent that any further fees are required during the pendency of this Application, including petition fees, the Commissioner is hereby authorized to charge payment of any additional fees, including any fees under 37 C.F.R. § 1.16 or 37 C.F.R. § 1.17, to Deposit Account No. 07-0153 of Gardere Wynne Sewell LLP and reference Attorney Docket No. 119941-1100.

Respectfully submitted,

GARDERE WYNNE SEWELL LLP



---

Scott C. Sample  
Registration No. 52,189  
(214) 999-4712 / (214) 999-3712  
ATTORNEY FOR APPLICANT

[October 30, 2008]